INTRODUCTION {#s1}
============

Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related death worldwide, with an estimated 500,000 to 1 million deaths per year \[[@R1], [@R2]\]. More than two-thirds of patients are diagnosed at an advanced stage, when curative treatments, including hepatic resection, radio-frequency ablation, and liver transplantation, are no longer an option \[[@R3]\]. Despite advances in surgical techniques and perioperative management, the overall prognosis of HCC remains poor due to a high recurrence rate and intrahepatic metastasis after curative resection \[[@R4]\]. It is therefore vital to identify novel predictive biomarkers that can be used to improve prognosis and select appropriate therapeutic strategies.

Systemic inflammatory responses play a critical role in the pathogenesis and progression of cancer \[[@R5]\]. Inflammation indicators, such as serum ferritin (SF), neutrophil-to-lymphocyte ratio (NLR), lymphocyte-to-monocyte ratio (LMR), platelet-to-lymphocyte ratio (PLR), and C-reactive protein (CRP) have been identified as prognostic indicators in various cancers \[[@R6]--[@R10]\]. Studies have also shown that platelets play multiple roles during inflammatory response processes. High platelet counts can promote cancer progression by facilitating neoangiogenesis, production of adhesion molecules and increases in early metastatic niches \[[@R11], [@R12]\]. By contrast, lymphocytes hinder malignant progression through tumoral infiltration by multiple lymphocyte subtypes. Low lymphocyte counts are often seen in patients with advanced cancer \[[@R13]\]. Moreover, a high platelet-to-lymphocyte ratio (PLR), which is defined as absolute platelet counts divided by lymphocyte counts, is reportedly linked to an unfavorable prognosis in multiple malignancies \[[@R10], [@R14], [@R15]\].

Nevertheless, the prognostic value of PLR in HCC has not yet been fully elucidated. Furthermore, there has been no systematic review or meta-analysis to determine the reliability and degree of its prognostic value. We therefore conducted a meta-analysis to assess the effects of pretreatment PLR on OS and DFS/RFS as well as the associations between PLR and the clinicopathological features of patients with HCC.

RESULTS {#s2}
=======

Study characteristics {#s2_1}
---------------------

The literature search of electronic databases identified a total of 186 articles. After duplicates removal, 115 articles were screened for eligibility. Of these, 95 were excluded through titles and abstracts, leaving 20 articles for detailed evaluation. Nine studies did not meet the inclusion criteria and were therefore excluded. Ultimately, 11 eligible studies, comprising a total of 2,507 patients, were considered eligible for the meta-analysis \[[@R16]--[@R26]\]. The PRISMA flow diagram of the study selection process was shown in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of the study selection process](oncotarget-07-81830-g001){#F1}

Of 11 studies, 10 studies were published in 2015 or later. Eight studies were from China, one from UK, one from USA, and one from Singapore. The sample sizes ranged from 116 to 414. Ten studies investigated the prognostic role of PLR in OS, and 5 studies explored the prognostic impact of PLR in DFS/RFS. The cut-off values for PLR ranged from 87.87 to 290, 4 studies used a PLR cut-off value ≥ 150, while 7 studies used a PLR \< 150. HRs and 95% CIs were extracted directly from the 9 studies. HRs in 2 studies were estimated by Kaplan-Meier survival curves. Characteristics of included studies are shown in Table [1](#T1){ref-type="table"}.

###### Characteristics of the studies included in the meta-analysis

  Author     Year   Country     Age (years)   Study type   Gender (M/F)   Ethnicity   Follow-up (months)   Treatment      No. of patients   Stage             Cut-off value   Survival analysis   HR estimate   Analysis
  ---------- ------ ----------- ------------- ------------ -------------- ----------- -------------------- -------------- ----------------- ----------------- --------------- ------------------- ------------- ----------
  D\'Emic    2016   USA         60(28-85)     R            52/64          Caucasian   12(5.3-18.1)         Mixed          116               Mixed             290             OS/PFS              Reported      MV/UV
  Fan        2015   China       49(23-75)     R            87/45          Asian       11(4--46)            Chemotherapy   132               Non- metastatic   137             OS                  Reported      MV/UV
  Goh        2016   Singapore   66 (21-85)    R            142/24         Asian       23(0-170)            Surgery        166               Mixed             290             OS/RFS              Reported      UV
  Ji         2016   China       51(21-79)     R            285/36         Asian       NA                   Surgery        321               Mixed             115             OS                  Reported      MV/UV
  Li(1)      2015   China       57 (19-86)    R            211/32         Asian       2.7(0.1-44.8)        Mixed          243               Metastatic        111.23          OS                  Reported      MV/UV
  Li(2)      2015   China       59.5±12.1     R            329/85         Asian       NA                   Mixed          414               Non- metastatic   87.87           RFS                 Estimated     MV
  Neofytou   2014   UK          NA            R            52/88          Caucasian   33(1-103)            Mixed          140               Metastatic        150             OS/DFS              Reported      MV/UV
  Peng       2015   China       50(21-78)     R            191/28         Asian       36.4(3-85.9)         Surgery        219               Mixed             ΔPLR 2.875      OS/RFS              Reported      MV/UV
  Tian       2016   China       56 (26-77)    R            107/15         Asian       22(3-118)            Chemotherapy   122               Mixed             96.13           OS                  Reported      MV/UV
  Xia        2015   China       49.4(19-71)   R            308/35         Asian       33.7(9.5-132)        Mixed          343               Mixed             125             OS/DFS              Estimated     MV
  Xue        2015   China       53.05±11.48   R            258/33         Asian       9                    Chemotherapy   291               Mixed             150             OS                  Reported      MV/UV

R: retrospective; H: high expression; L: low expression; OS: overall survival; DFS: disease-free survival; RFS: recurrence-free survival; MV: multivariate; NA: not available.

Quality assessment {#s2_2}
------------------

In methodological quality of studies, the global quality score ranged 50.0% to 70.0%, with a median of 67.6% (Table [2](#T2){ref-type="table"}). The subscore of laboratory methodology had the lowest value, with a median quality score of 5.8 out of 14. The most poorly described items were the blinding evaluation, tissue sample conservation, and description of the revelation test procedure.

###### Methodological assessments of the studies included in the meta-analysis

  Author     Global score (%)   Scientific design (/10)   Laboratory methodology (/14)   Generalizability (/12)   Results analysis (/8)
  ---------- ------------------ ------------------------- ------------------------------ ------------------------ -----------------------
  D\'Emic    65.9               7                         6                              9                        7
  Fan        72.7               7                         6                              12                       7
  Goh        65.9               8                         6                              8                        7
  Ji         70.5               9                         6                              10                       6
  Li(1)      70.5               8                         4                              11                       8
  Li(2)      61.4               7                         6                              10                       4
  Neofytou   70.5               9                         6                              8                        8
  Peng       68.2               7                         6                              10                       7
  Tian       72.7               8                         6                              10                       8
  Xia        50.0               6                         6                              6                        4
  Xue        75.0               9                         6                              10                       8

Meta-analysis {#s2_3}
-------------

### Overall survival {#s2_3_1}

Ten studies involving 2,093 patients investigated the association between PLR and OS. Elevated PLR was significantly associated with poor OS (HR = 1.78; 95% CI = 1.36-2.34; P \< 0.001; Figure [2](#F2){ref-type="fig"}). The test for heterogeneity was significant, thus, the random-effects model was used (I^2^ = 89%; P \< 0.001). To detect the potential heterogeneity, subgroup analyses stratified by ethnicity, treatment, sample size, disease stage, HR estimation, analysis method, ELCWP score, and the cut-off value of PLR (Table [3](#T3){ref-type="table"}). Exploratory subgroup analysis according to ethnicity showed that elevated PLR had more significantly prognostic value for OS in Asian populations (HR = 1.88; 95% CI = 1.33-2.65; P \< 0.001). Pooled HRs for OS stratified by treatment, the negative effect of elevated PLR on OS was observed in patients receiving chemotherapy (HR = 1.77; 95% CI = 1.43-2.21; P \< 0.001), surgery (HR = 2.38; 95% CI = 1.17-4.84; P = 0.02), and mixed methods (HR = 1.40; 95% CI = 1.01-1.92; P = 0.04). In the subgroup analysis by disease stage, patients with high PLR had significantly worse OS in patients with non-metastatic disease (pooled HR = 2.68; 95% CI = 1.55-4.63; P \< 0.001) and mixed subgroup (HR = 1.79; 95% CI = 1.39-2.29; P \< 0.001). The cut-off values ranged from 87.87 to 290. We stratified cut-off values into two subgroups: \<150 and ≥150. Stratification by the cut-off value showed the OS rate was significantly worse in all subgroups. In addition, subgroup analyses suggested that high PLR predicted poor OS in patient with HCC, regardless of the sample size (\<200 and ≥200), HR estimation (reported and estimated), analysis method (univariate and multivariate), and ELCWP score (\<70 and ≥70).

![Forest plots for the association between PLR expression and OS](oncotarget-07-81830-g002){#F2}

###### Pooled hazard ratios (HRs) for OS according to subgroup analyses

  Subgroup                               No. of studies   No. of patients   Effects model   HR (95% CI)         P value   Heterogeneity   
  -------------------------------------- ---------------- ----------------- --------------- ------------------- --------- --------------- ----------
  Overall                                10               2093              Random          1.78 (1.36, 2.34)   \<0.001   89              \< 0.001
  Ethnicity                                                                                                                               
   Asian                                 8                1837              Random          1.88 (1.33, 2.65)   \<0.001   91              \<0.001
   Caucasian                             2                256               Random          1.50 (0.94, 2.40)   0.09      51              0.15
  Treatment                                                                                                                               
   Chemotherapy                          3                545               Fixed           1.77 (1.43, 2.21)   \<0.001   40              0.19
   Surgery                               3                706               Random          2.38 (1.17, 4.84)   0.02      84              0.002
   Mixed                                 6                842               Random          1.40 (1.01, 1.92)   0.04      86              \< 0.001
  Sample size                                                                                                                             
   \<200                                 5                676               Random          1.85 (1.35, 2.53)   \<0.001   58              0.05
   ≥200                                  5                1417              Random          1.71 (1.14, 2.57)   0.009     92              \< 0.001
  Disease stage                                                                                                                           
   Non-metastatic                        1                132               \-              2.68 (1.55, 4.63)   \<0.001   \-              \-
   Mixed (non-metastatic & metastatic)   7                1578              Random          1.79 (1.39, 2.29)   \<0.001   69              0.004
   Metastatic                            2                383               Random          1.36 (0.65, 2.85)   0.41      79              0.03
  Cut-off for PLR                                                                                                                         
   \<150                                 6                1380              Random          1.96 (1.25, 3.06)   0.003     91              \< 0.001
   ≥150                                  4                713               Fixed           1.46 (1.25, 1.71)   \<0.001   31              0.23
  HR estimation                                                                                                                           
   Reported                              9                1750              Random          1.76 (1.32, 2.33)   \<0.001   89              \< 0.001
   Estimated                             1                343               \-              1.98 (1.33, 2.95)   \<0.001   \-              \-
  Analysis method                                                                                                                         
   Univariate                            1                166               \-              1.99 (1.21, 3.27)   0.006     \-              \-
   Multivariate                          9                1927              Random          1.76 (1.33, 2.34)   \<0.001   90              \<0.001
  ELCWP score                                                                                                                             
   \<70                                  4                844               Random          2.14 (1.29, 3.56)   0.003     83              \< 0.001
   ≥70                                   6                1249              Random          1.61 (1.15, 2.24)   0.005     87              \< 0.001

Disease-free survival/recurrence-free survival {#s2_4}
----------------------------------------------

Five studies comprising 1,282 patients evaluated the association between PLR and DFS/RFS. In comparison with a low PLR, a high PLR was significantly correlated with worse DFS/RFS (HR = 1.82; 95% CI = 1.56-2.13; P \< 0.001; Figure [3](#F3){ref-type="fig"}), without significant heterogeneity (I^2^ = 17%; P = 0.31).

![Forest plots for the association between PLR expression and DFS/RFS](oncotarget-07-81830-g003){#F3}

Clinicopathological parameters {#s2_5}
------------------------------

In the meta-analysis, we identified 12 clinical factors to explore the impact of PLR on the clinical features in HCC. Pooled data revealed that a high PLR was significantly related to tumor size (\> 3 cm vs. \< 3 cm; HR = 1.67, 95% CI: 1.11-2.52, P = 0.01), TNM stage (III-IV vs. I-II; HR = 2.20, 95% CI: 1.11-4.33, P = 0.02), lymph node metastasis (pos vs. neg; HR = 1.62, 95% CI: 1.01-2.60, P = 0.04), distant metastasis (pos vs. neg; HR = 2.38, 95% CI: 1.23-4.60, P = 0.01), and vascular invasion (pos vs. neg; HR = 1.70, 95% CI: 1.20-2.43, P = 0.003). Whereas no significant association was found with gender (male vs. female), cirrhosis (yes vs. no), AFP (\>400 ng/mL vs. \<400 ng/mL), Child-Pugh classification (B/C vs. A), differentiation (low vs. moderate/high), tumor number (\> 3 cm vs. \< 3 cm), tumor size (\> 5 cm vs. \< 5 cm), and tumor distribution (bilobar vs. unilobar). The correlation between PLR expression and clinicopathological parameters of HCC is shown in Table [4](#T4){ref-type="table"}.

###### Meta-analysis of the association between PLR and clinicopathological features of HCC

  Characteristics                             No. of studies   No. of patients   OR (95% CI)          p       Heterogeneity   
  ------------------------------------------- ---------------- ----------------- -------------------- ------- --------------- ----------
  Gender (male vs. female)                    9                2070              0.79 (0.61, 1.01)    0.06    0               0.57
  Cirrhosis (yes vs. no)                      4                1090              1.88 (0.22, 16.26)   0.57    97              \< 0.001
  AFP(\>400 ng/mL vs. \<400 ng/mL)            4                764               1.13 (0.83, 1.52)    0.44    34              0.21
  Child-Pugh classification (B/C vs. A)       4                911               0.94 (0.62, 1.42)    0.76    46              0.14
  Differentiation ( low vs. moderate/high)    3                976               1.01 (0.42, 2.42)    0.99    72              0.03
  Tumor number (\> 3 cm vs. \< 3 cm)          3                615               0.45 (0.14, 1.47)    0.19    87              \< 0.001
  Tumor size (\> 3 cm vs. \< 3 cm)            3                473               1.67 (1.11, 2.52)    0.01    26              0.26
  Tumor size (\> 5 cm vs. \< 5 cm)            2                483               2.07 (0.29, 14.62)   0.46    93              \< 0.001
  Tumor distribution (bilobar vs. unilobar)   2                306               1.17 (0.68, 2.03)    0.56    26              0.24
  TNM stage (III-IV vs. I-II)                 3                531               2.20 (1.11, 4.33)    0.02    61              0.07
  Lymph node metastasis (pos vs. neg)         2                365               1.62 (1.01, 2.60)    0.04    0               0.83
  Distant metastasis (pos vs. neg)            1                243               2.38 (1.23, 4.60)    0.01    \-              \-
  Vascular invasion (pos vs. neg)             4                860               1.70 (1.20, 2.43)    0.003   0               0.41

Sensitivity analysis and publication bias {#s2_6}
-----------------------------------------

Each single study was removed each time to estimate the influence of individual data sets on the combined HR. The results of sensitivity analysis showed that no study had a significant effect on the observed effect size (pooled HR), indicating the robustness of our findings. Evidence of publication bias was observed for OS (P = 0.074 for Begg\'s test and P \< 0.001 for Egger\'s test), while no significant publication bias was detected for DFS/RFS by both the Begg\'s test (P = 1.000) and the Egger\'s test (P = 0.864). Using "trim and fill" method, we assessed the impact of this bias and the HR for OS didn\'t show a shift.

DISCUSSION {#s3}
==========

HCC has been shown to be an inflammation-induced cancer \[[@R27]\]. Approximately 80% of HCC cases are related to chronic HBV or HCV infections \[[@R28]\]. Recently, several clinical studies showed that a high PLR correlates with worse prognosis and clinicopathologic features in patients with HCC \[[@R18], [@R19], [@R29]\]. Moreover, Tian et al. found that elevated pretreatment PLR is predictive of poor OS among patients with HBV-related HCC \[[@R24]\]. Similarly, Fan et al. reported that a high PLR correlates significantly with a poor prognosis and metastasis in recurrent HCC patients \[[@R17]\]. PLR has also been shown to correlate with recurrence and survival rates in patients with HCC \[[@R29]\]. These findings suggest PLR could serve as a promising prognostic or therapeutic target for HCC patients. To our knowledge, this is the first meta-analysis investigating the correlation between PLR and survival or clinicopathological features in patients with HCC.

We identified 11 studies involving 2,507 patients that evaluated the clinical relevance and prognostic value of PLR in patients with HCC. This meta-analysis showed that elevated PLR is an unfavorable prognostic factor for OS and DFS/RFS in patients with HCC. Subgroup analyses revealed that the negative prognostic effect of elevated PLR remained substantial despite different sample sizes, cut-off values, treatment methods, HR estimation methods, analysis methods, and ELCWP scores. However, a stratified analysis showed that a high PLR had no prognostic efficiency for OS in Caucasian or metastatic patients. Additionally, when we further analyzed the correlations between pretreatment PLR and clinicopathologic parameters, we found that elevated PLR was linked with tumor size \> 3 cm, TNM stage, lymph node metastasis, distant metastasis, and vascular invasion.

The mechanisms responsible for the association between high PLR and poor outcome in HCC remain unclear. However, mounting evidence suggests that systemic inflammation plays an important role in tumor initiation and progression by contributing to genomic instability, genetic mutations, cancer cell proliferation, angiogenesis, and hematogenous metastasis \[[@R13], [@R30]\]. Cancer-related inflammation can suppress antitumor immunity by recruiting immunosuppressive cells such as myeloid-derived suppressor cells and regulatory T cells, resulting in tumor progression \[[@R31], [@R32]\].

It has been suggested that there is cross-talk between the inflammatory response and tumor progression \[[@R5], [@R13], [@R33]\]. It is now generally accepted that platelets bind VEGF, PDGF, FGF, and TGF-β family proteins, enabling platelets to act as a reservoir for secreted growth factors that increase tumor angiogenesis, cell proliferation, migration, and metastasis \[[@R34]--[@R36]\]. Tumor-infiltrating lymphocytes (TILs) are important immune cells found within tumors and are responsible for antitumor immune responses \[[@R37]\]. High numbers of TILs correlate with favorable clinical outcomes \[[@R38], [@R39]\]. In HCC patients, high levels of tumor-infiltrating CD4+ T lymphocytes are associated with a lower recurrence rate and better prognosis \[[@R40]\]. This suggests PLR combined with the effects of platelets and lymphocytes may be predictive of prognosis in patients with HCC.

This meta-analysis has several limitations. First, significant heterogeneity was found among studies. However, subgroup analyses showed that the heterogeneity diminished or disappeared in patients receiving chemotherapy, and the cut-off for PLR ≥150. Moreover, the stability of our results was confirmed by sensitivity analysis. Second, the cut-off value for PLR differed among the studies. This may be a significant contributor to the heterogeneity. Third, publication bias was detected for OS. As we know, studies with negative results are less likely to be published than those with positive results. Additionally, only published articles were included, and they were all written in English. Therefore, the summary statistics obtained may not approximate the actual average. However, using the "Trim and Fill" method to evaluate this bias, the pooled effect size remained significant. This indicates the reliability of our results. Fourth, HRs and their 95% CIs were extracted from univariable analyses in only one study and estimated from Kaplan-Meier survival curves in two studies. Thus, the prognostic value of PLR may be overestimated.

In conclusion, our meta-analysis confirms that an elevated pretreatment PLR is significantly associated with poor survival in conjunction with advanced tumor stage and positive metastasis in HCC patients. This suggests pretreatment PLR could provide essential information that informs prognosis and treatment decisions for patients HCC.

MATERIALS AND METHODS {#s4}
=====================

Search strategies {#s4_1}
-----------------

A comprehensive search of MEDLINE, EMBASE, and Cochrane databases from the inception to July 2016 was performed. The following MeSH terms and text words were used in combination: "hepatocellular carcinoma" or "HCC" or "liver cancer" or "liver tumor" or "liver neoplasms" or "liver cell carcinoma", "platelet to lymphocyte ratio" or "PLR" or "platelet lymphocyte ratio" or "platelet-lymphocyte ratio", "prognostic" or "prognosis" or "survival" or "recurrence" or "outcome". In addition, the references of eligible studies, pertinent reviews, and meta-analyses in this field were screened.

Study selection {#s4_2}
---------------

The criteria for inclusion were listed as follows: (1) the diagnosis of HCC was pathologically confirmed. (2) assessing the prognostic value of pretreatment PLR on OS, DFS and/or RFS; (3) reporting a sufficient information to estimate the hazard ratio (HR) and 95% confidence interval (CI); (4) reporting a dichotomous cut-off value for PLR; and (5) original high-quality English articles. The exclusion criteria were: (1) abstract, reviews, conference, case reports, and expert opinion; (2) reporting PLR only as a continuous variable; (3) lacking essential information for calculating an HR and 95% CI; and (4) overlapping or duplicate data.

Data extraction {#s4_3}
---------------

The following information was captured using data abstraction forms:

first author\'s name, year of publication, study design, country, ethnicity, patient ages and genders, number of patients, disease stage, treatment, follow-up, cut-off value, outcome measures (HRs for OS, DFS, or RFS, as well as their 95% CIs), survival analysis methods, and clinicopathological features. HRs were directly extracted from multivariate or univariate analyses or estimated from Kaplan-Meier survival curves independently by two reviewers and any discrepancies were resolved a third reviewer.

Quality assessment {#s4_4}
------------------

The quality of each study was evaluated in accordance with the revised ELCWP scoring scale described by Steel et al. \[[@R41]\]. Each item was assessed using an ordinal scale (possible values: 2, 1, 0). The overall score include the following four categories: (1) scientific design: 0-10; (2) laboratory methodology: 0-14; (3) generalizability: 0-12; (4) results analysis: 0-8. The total scores ranged from 0 to 44. The final scores are expressed as percentages, with a higher scores reflecting a better methodological quality.

Statistical analyses {#s4_5}
--------------------

The meta-analysis was conducted by RevMan 5.3 software (Cochrane Collaboration, Copenhagen, Denmark) and STATA 12.0 (College Station, TX, USA). HRs and their 95% CIs were searched in the original articles or extrapolated using methods described by Tierney and Parmar \[[@R42], [@R43]\]. The associations between PLR and clinicopathologic features were expressed as odds ratios (ORs) and its 95 % CIs. Statistical heterogeneity among eligible studies was estimated using Cochrane\'s Q statistic and I^2^ statistic \[[@R44]\]. A p-value \< 0.1 for the Q-test or I^2^ \>50% was considered statistically significant. When there was no statistically significant heterogeneity, we used the fixed-effects model for pooling the results; otherwise, the random-effects model was applied. Subgroup analyses stratified by ethnicity, treatment, sample size, disease stage, HR estimation, analysis method, ELCWP score, and the cut-off value of PLR. In order to evaluate the robustness of conclusions, sensitivity analysis was performed by excluding single study at a time from the meta-analysis to explore its influence on the pooled HR for OS. Publication bias was evaluated using Begg\'s funnel plots and Egger\'s tests. When publication bias was identified, we used the "Trim and Fill" method to re-estimate a corrected effect size after adjustment for publication bias \[[@R45]\]. P \< 0.05 was defined as statistically significant.
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